0001415889-24-001831.txt : 20240125
0001415889-24-001831.hdr.sgml : 20240125
20240125200034
ACCESSION NUMBER: 0001415889-24-001831
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240123
FILED AS OF DATE: 20240125
DATE AS OF CHANGE: 20240125
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MIDDLETON FRED A
CENTRAL INDEX KEY: 0001267959
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39538
FILM NUMBER: 24563796
MAIL ADDRESS:
STREET 1: 400 SOUTH EL CAMINO REAL STE 1200
CITY: SAN MATEO
STATE: CA
ZIP: 94402-1708
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CalciMedica, Inc.
CENTRAL INDEX KEY: 0001534133
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 452120079
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 505 COAST BOULEVARD SOUTH
STREET 2: SUITE 307
CITY: LA JOLLA
STATE: CA
ZIP: 92037
BUSINESS PHONE: 858-952-5500
MAIL ADDRESS:
STREET 1: 505 COAST BOULEVARD SOUTH
STREET 2: SUITE 307
CITY: LA JOLLA
STATE: CA
ZIP: 92037
FORMER COMPANY:
FORMER CONFORMED NAME: CalciMedica, Inc. /DE/
DATE OF NAME CHANGE: 20230322
FORMER COMPANY:
FORMER CONFORMED NAME: GRAYBUG VISION, INC.
DATE OF NAME CHANGE: 20170717
FORMER COMPANY:
FORMER CONFORMED NAME: GRAYBUG, Inc.
DATE OF NAME CHANGE: 20150303
4
1
form4-01252024_080106.xml
X0508
4
2024-01-23
0001534133
CalciMedica, Inc.
CALC
0001267959
MIDDLETON FRED A
C/O CALCIMEDICA, INC.
505 COAST BLVD. S. #307
LA JOLLA
CA
92037
true
false
true
false
0
Common Stock
2024-01-23
4
P
0
243356
3.702
A
946744
I
By Sanderling Venture Partners VI, LP
Common Stock
2024-01-23
4
P
0
144676
3.702
A
727433
I
By Sanderling Venture Partners VI Co-Investment Fund, L.P.
Common Stock
2024-01-23
4
P
0
194472
3.702
A
435148
I
By Sanderling Ventures VII, L.P.
Common Stock
2024-01-23
4
P
0
51032
3.702
A
114260
I
By Sanderling Ventures VII (Canada), L.P.
Common Stock
2024-01-23
4
P
0
13184
3.702
A
27609
I
By Sanderling Ventures VII Annex Fund, L.P.
Common Stock
2024-01-23
4
P
0
3920
3.702
A
21602
I
By Sanderling Ventures Management VI
Common Stock
2024-01-23
4
P
0
28744
3.702
A
30292
I
By Sanderling Ventures Management VII
Common Stock
11714
D
Common Stock
8176
I
By Golden Triangle Ventures, LLC
Warrant
5.36
2024-01-23
4
P
0
121678
0.125
A
2024-01-23
2024-12-31
Common Stock
121678
121678
I
By Sanderling Venture Partners VI, LP
Warrant
7.15
2024-01-23
4
P
0
121678
0.125
A
2024-01-23
2026-12-31
Common Stock
121678
121678
I
By Sanderling Venture Partners VI, LP
Warrant
5.36
2024-01-23
4
P
0
72338
0.125
A
2024-01-23
2024-12-31
Common Stock
72338
72338
I
By Sanderling Venture Partners VI Co-Investment Fund, L.P.
Warrant
7.15
2024-01-23
4
P
0
72338
0.125
A
2024-01-23
2026-12-31
Common Stock
72338
72338
I
By Sanderling Venture Partners VI Co-Investment Fund, L.P.
Warrant
5.36
2024-01-23
4
P
0
97236
0.125
A
2024-01-23
2024-12-31
Common Stock
97236
97236
I
By Sanderling Ventures VII, L.P.
Warrant
7.15
2024-01-23
4
P
0
97236
0.125
A
2024-01-23
2026-12-31
Common Stock
97236
97236
I
By Sanderling Ventures VII, L.P.
Warrant
5.36
2024-01-23
4
P
0
25516
0.125
A
2024-01-23
2024-12-31
Common Stock
25516
25516
I
By Sanderling Ventures VII (Canada), L.P.
Warrant
7.15
2024-01-23
4
P
0
25516
0.125
A
2024-01-23
2026-12-31
Common Stock
25516
25516
I
By Sanderling Ventures VII (Canada), L.P.
Warrant
5.36
2024-01-23
4
P
0
6592
0.125
A
2024-01-23
2024-12-31
Common Stock
6592
6592
I
By Sanderling Ventures VII Annex Fund, L.P.
Warrant
7.15
2024-01-23
4
P
0
6592
0.125
A
2024-01-23
2026-12-31
Common Stock
6592
6592
I
By Sanderling Ventures VII Annex Fund, L.P.
Warrant
5.36
2024-01-23
4
P
0
1960
0.125
A
2024-01-23
2024-12-31
Common Stock
1960
1960
I
By Sanderling Ventures Management VI
Warrant
7.15
2024-01-23
4
P
0
1960
0.125
A
2024-01-23
2026-12-31
Common Stock
1960
1960
I
By Sanderling Ventures Management VI
Warrant
5.36
2024-01-23
4
P
0
14372
0.125
A
2024-01-23
2024-12-31
Common Stock
14372
14372
I
By Sanderling Ventures Management VII
Warrant
7.15
2024-01-23
4
P
0
14372
0.125
A
2024-01-23
2026-12-31
Common Stock
14372
14372
I
By Sanderling Ventures Management VII
The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.
The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the securities of the Issuer held by Sanderling Venture Partners VI, LP ("SVP VI, LP", together with Sanderling Venture Partners VI Co-Investment Fund, L.P., Sanderling VI Beteiligungs GmbH & Co. KG, Sanderling Ventures Management VI and Sanderling VI Limited Partnership (the "Sanderling VI Shares"). The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the securities of the Issuer held by Sanderling Ventures VII, LP ("SVP VII, LP", together with Sanderling Ventures Management VII, Sanderling Ventures VII (Canada), L.P. and Sanderling Ventures VII Annex Fund, L.P., the "Sanderling VII Shares"). The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
The Reporting Person is a managing member of Golden Triangle Ventures LLC and may be deemed to beneficially own the securities of the Issuer held by Golden Triangle Ventures LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.
The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.
/s/ John Dunn, Attorney-in-Fact
2024-01-25